HC Wainwright Predicts Lower Earnings for MiNK Therapeutics

MiNK Therapeutics, Inc. (NASDAQ:INKT) – Research analysts at HC Wainwright reduced their Q1 2025 earnings per share (EPS) estimates for MiNK Therapeutics in a report released on Tuesday, March 18th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings per share of ($0.63) for the quarter, down from their prior estimate of ($0.51). HC Wainwright currently has a “Buy” rating and a $35.00 price target on the stock. The consensus estimate for MiNK Therapeutics’ current full-year earnings is ($2.75) per share. HC Wainwright also issued estimates for MiNK Therapeutics’ Q2 2025 earnings at ($0.35) EPS, Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.36) EPS, FY2025 earnings at ($1.51) EPS, FY2026 earnings at ($0.87) EPS, FY2027 earnings at ($0.74) EPS, FY2028 earnings at ($0.32) EPS and FY2029 earnings at $0.12 EPS.

MiNK Therapeutics Stock Up 6.2 %

NASDAQ INKT opened at $8.41 on Friday. The stock’s 50-day simple moving average is $8.92 and its two-hundred day simple moving average is $7.75. MiNK Therapeutics has a twelve month low of $4.56 and a twelve month high of $19.00. The company has a market capitalization of $33.33 million, a price-to-earnings ratio of -2.16 and a beta of 0.16.

MiNK Therapeutics (NASDAQ:INKT) last released its quarterly earnings results on Tuesday, March 18th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.12).

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.